Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma Findings provide an immunological mechanism
LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON's Commitment to Its
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President
Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29,
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxicities or serious
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property with an
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- IMUNON,
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones A patient treated with IMNN-001 will share firsthand
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3
LAWRENCEVILLE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a
Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company’s large, randomized Phase II study, OVATION 2Strong enrollment
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism First-of-its-kind meeting spotlights IMNN-001 as
Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA clearance with IMNN-001 vs.
